A 12-Week Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of GRC 8200, a New Oral DPP IV Inhibitor, in Patients With Type 2 Diabetes Mellitus.

Trial Profile

A 12-Week Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of GRC 8200, a New Oral DPP IV Inhibitor, in Patients With Type 2 Diabetes Mellitus.

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Sep 2015

At a glance

  • Drugs Melogliptin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Glenmark Pharmaceuticals Ltd
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 18 Oct 2009 Results presented at the 20th World Diabetes Congress (WDC).
    • 25 Sep 2009 Planned end date changed from 1 May 2009 to 1 Oct 2009 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top